Thiazolidinediones.
Yki-Järvinen
Hannele
H
Division of Diabetes, Department of Medicine, University of Helsinki, Finland. ykijarvi@cc.helsinki.fi
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005234:Fatty Liver / Q000188:drug therapy; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D008060:Lipodystrophy / Q000188:drug therapy; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D012307:Risk Factors; D045162:Thiazolidinediones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014157:Transcription Factors / Q000378:metabolism*
D015415:Biomarkers; D007004:Hypoglycemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D045162:Thiazolidinediones; D014157:Transcription Factors